Prazosin Hydrochloride — Veterinary Vademecum Drug Reference

Dosage & Administration Guidelines

Species	Route	Dose	Frequency	Duration & Clinical Notes
Dog	PO	0.5-1 mg/kg (up to 2 mg/kg) or 1-2 mg per dog (small dogs) to 5-10 mg per dog (large dogs)	q8-12h	Duration: As needed for condition; often long-term for urethral obstruction Notes: Start at low end of dose and titrate to effect. For hypertension, adjust based on blood pressure monitoring.
Cat	PO	0.25-0.5 mg per cat (or 0.03-0.1 mg/kg)	q12-24h	Duration: As needed; often short-term for urethral spasm Notes: Use cautiously in cats; monitor for hypotension and sedation.
Horse	PO	Not established; experimental doses of 0.02-0.05 mg/kg have been used	q12h	Duration: Not defined Notes: Not recommended for routine use; limited data.
Rabbit	PO	0.5-1 mg/kg	q12-24h	Duration: As needed Notes: Use with caution; monitor for hypotension.

Clinical Indications & Species Uses

General Indications

Hypertension
Functional urethral obstruction (reflex dyssynergia, urethral spasm)

Dog (Canine)

Functional urethral obstruction (e.g., reflex dyssynergia, urethral spasm)
Hypertension (especially when other agents are ineffective or contraindicated)
Adjunct in the management of congestive heart failure (to reduce afterload)

Cat (Feline)

Functional urethral obstruction (e.g., urethral spasm, feline lower urinary tract disease)
Hypertension (less commonly used; other agents preferred)

Pharmacology & Mechanism of Action

Drug Class: Alpha-1 Adrenergic Antagonist | Pharmacological Group: Antihypertensive / Urethral Relaxant

Mechanism of Action: Prazosin is a selective, competitive antagonist at postsynaptic alpha-1 adrenergic receptors. By blocking these receptors in vascular smooth muscle, it causes vasodilation of both resistance and capacitance vessels, leading to a decrease in peripheral vascular resistance and blood pressure. In the lower urinary tract, alpha-1 blockade relaxes smooth muscle in the urethra, prostate, and bladder neck, reducing urethral pressure and outflow resistance. This dual action makes it useful for both hypertension and functional urethral obstruction.

Pharmacodynamics: Prazosin produces a balanced vasodilation with a reduction in mean arterial pressure. It does not typically cause reflex tachycardia because it also blocks alpha-1 receptors in the heart, though some reflex increase in heart rate may occur. In the urinary tract, it decreases urethral pressure and increases urinary flow. The onset of action after oral administration is within 30-90 minutes, with peak effects at 2-4 hours. The duration of effect is approximately 8-12 hours in most species.

⚡ Pharmacokinetics Summary

Absorption: Prazosin is well absorbed after oral administration, with peak plasma concentrations occurring 1-3 hours post-dose. Food may delay absorption but does not significantly reduce the extent.

Distribution: Prazosin is widely distributed throughout the body. It crosses the blood-brain barrier to a limited extent. It is highly protein-bound (approximately 97%) in plasma. It crosses the placenta and is excreted in milk.

Metabolism: Prazosin is extensively metabolized in the liver, primarily by demethylation and conjugation. The metabolites are less active than the parent compound.

Excretion: The metabolites are excreted primarily in bile and feces, with a small amount (about 6-10%) excreted in urine as unchanged drug. The elimination half-life in dogs is approximately 2-3 hours, but the pharmacodynamic effect lasts longer.

Half-Life: Dogs: 2-3 hours; Cats: approximately 2 hours; Humans: 2-3 hours (reference)

Bioavailability: Oral bioavailability is approximately 50-60% due to first-pass metabolism.

Protein Binding: Approximately 97% bound to plasma proteins

Available Formulations & Strengths

Oral Capsule 1 mg, 2 mg, 5 mg (PO)

Oral Tablet 1 mg, 2 mg, 5 mg (PO)

Contraindications & Clinical Warnings

Contraindications:

Hypersensitivity to prazosin or other quinazoline derivatives
Severe hypotension or shock
Concurrent use with phosphodiesterase-5 inhibitors (e.g., sildenafil) due to risk of severe hypotension

Warnings & Clinical Precautions:

Use with caution in patients with renal or hepatic impairment.
May cause hypotension, especially after the first dose (first-dose effect).
Use with caution in animals with cerebral or coronary insufficiency.
In cats, use with caution due to potential for profound hypotension and sedation.
May cause syncope in some animals.
Monitor blood pressure during dose titration.
Use with caution in animals with a history of priapism (rare).

Adverse Effects & Reactions

Common:

Sedation
Lethargy
Weakness
Hypotension
Dizziness (ataxia)
Gastrointestinal upset (vomiting, diarrhea)

Serious / Severe:

Severe hypotension
Syncope
Cardiovascular collapse (rare)
Paradoxical hypertension (rare)

Rare:

Priapism
Allergic reactions (rash, urticaria)
Hepatotoxicity (rare)
Blood dyscrasias (rare)

Key Drug Interactions

Interacting Drug / Class	Clinical Effect & Mechanism	Severity
Other antihypertensives (e.g., ACE inhibitors, beta-blockers, calcium channel blockers)	Additive hypotensive effects; may cause severe hypotension.	High
Phosphodiesterase-5 inhibitors (e.g., sildenafil, tadalafil)	Severe hypotension due to additive vasodilation.	High
Diuretics	Increased risk of hypotension and electrolyte imbalances.	Moderate
Nonsteroidal anti-inflammatory drugs (NSAIDs)	May reduce antihypertensive effect due to sodium and water retention.	Moderate
Sympathomimetics (e.g., epinephrine, norepinephrine)	May antagonize the effects of prazosin; potential for paradoxical hypertension.	Moderate

Overdose & Toxicity Management

Signs of Toxicity:

Severe hypotension
Drowsiness
Collapse
Bradycardia
Shock

Emergency Treatment Protocol: Treatment is symptomatic and supportive. Induce emesis if recent ingestion and animal is conscious. Administer activated charcoal to reduce absorption. Provide intravenous fluids to support blood pressure. Administer vasopressors (e.g., norepinephrine, phenylephrine) if severe hypotension persists. Monitor cardiac function and blood pressure closely. There is no specific antidote.

Food Animal Withdrawal Times

Not approved for food animals; no withdrawal times established. Use in food animals is off-label and prohibited in some jurisdictions.

Storage, Handling & Regulatory Information

Storage Temperature: Store at room temperature (20-25°C, 68-77°F) in a tight, light-resistant container.

Light Sensitivity: Light-sensitive — protect from direct exposure.

Handling & Special Conditions: Protect from moisture and light. Keep out of reach of children and animals.

Dispensing Status: Prescription Required (Rx Only)

Approval Status: Approved for human use; not FDA-approved for veterinary use, but commonly used off-label in dogs and cats.

Extra-Label (Off-Label) Use: In the US, extra-label use in food animals is prohibited if the drug is not approved for that species and if there is no established withdrawal time. In companion animals, extra-label use is common and permitted under veterinary discretion.

Clinical Pearls & Practice Notes

💡 Clinical Insights: Prazosin is primarily used in veterinary medicine for the management of functional urethral obstruction, particularly in dogs with reflex dyssynergia and cats with urethral spasm. It is also used as an antihypertensive agent, though other drugs (e.g., amlodipine, ACE inhibitors) are often preferred. The drug is well-tolerated but can cause significant hypotension, especially at the start of therapy. It is important to start with a low dose and titrate to effect, monitoring blood pressure and clinical response. In cats, dosing is often based on body weight or fixed low doses. Prazosin should be used with caution in animals with cardiovascular disease or those receiving other vasodilators. Client education should include signs of hypotension (weakness, lethargy, collapse) and the importance of regular monitoring. For urethral obstruction, prazosin is often used in combination with other therapies such as anti-inflammatories or muscle relaxants.

References & Literature

📚 Plumb's Veterinary Drug Handbook
📚 Papich Veterinary Pharmacology and Therapeutics
📚 Compendium of Veterinary Products (CVP)